Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Burning Rock Biotech Limited (BNR)

2.66   -0.25 (-8.59%) 07-02 19:15
Open: 2.98 Pre. Close: 2.91
High: 2.94 Low: 2.45
Volume: 1,107,484 Market Cap: 280(M)
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.98 - 3 3 - 3.01
Low: 2.42 - 2.43 2.43 - 2.44
Close: 2.64 - 2.66 2.66 - 2.68

Technical analysis

as of: 2022-07-01 4:20:31 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.73     One year: 4.36
Support: Support1: 2.29    Support2: 1.74
Resistance: Resistance1: 3.2    Resistance2: 3.73
Pivot: 2.24
Moving Average: MA(5): 2.59     MA(20): 2.2
MA(100): 5.77     MA(250): 11.88
MACD: MACD(12,26): -0.2     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 77.3     %D(3): 77.1
RSI: RSI(14): 51.4
52-week: High: 28.6  Low: 1.74
Average Vol(K): 3-Month: 776 (K)  10-Days: 1,660 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BNR ] has closed below upper band by 18.0%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 01 Jul 2022
Burning Rock Biotech Ltd (BNR) Stock Is Higher By 11.34% This Week: Buy, Hold, or Sell? - InvestorsObserver

Thu, 30 Jun 2022
Burning Rock Biotech (BNR) Announces the Launch of China's First Prospective Interventional Validation Study on Multi-Cancer Early Detection -

Wed, 29 Jun 2022
Research Analysts' Weekly Ratings Changes for Brenntag (BNR) - Defense World

Tue, 21 Jun 2022
Is Burning Rock Biotech Ltd (BNR) Stock a Bad Value? - InvestorsObserver

Tue, 21 Jun 2022
Burning Rock Biotech announces $10M stock buyback plan (NASDAQ:BNR) - Seeking Alpha

Wed, 15 Jun 2022
Brenntag (FRA:BNR) Given a €95.00 Price Target at Barclays - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 105 (M)
Shares Float 36 (M)
% Held by Insiders 5.8 (%)
% Held by Institutions 52.9 (%)
Shares Short 1,210 (K)
Shares Short P.Month 1,340 (K)

Stock Financials

EPS -1.06
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 19.77
Profit Margin (%) -156.9
Operating Margin (%) -157
Return on Assets (ttm) -20.2
Return on Equity (ttm) -37.4
Qtrly Rev. Growth 11.8
Gross Profit (p.s.) 3.48
Sales Per Share 4.85
EBITDA (p.s.) -7.32
Qtrly Earnings Growth 0
Operating Cash Flow -478 (M)
Levered Free Cash Flow -141 (M)

Stock Valuations

PE Ratio -2.52
PEG Ratio -8
Price to Book value 0.13
Price to Sales 0.54
Price to Cash Flow -0.59

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.